Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 3,910 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension Clear all
Completed Not applicable Interventional

Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension

NCT05393232
View directory record Official record
Conditions
Hypertension
Interventions
Dietitian-Assisted DASH groceries, Self-directed shopping
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 28, 2026, 7:47 PM EDT
Terminated Phase 4 Interventional Results available

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

NCT01349114
View directory record Official record
Conditions
Diabetes, Pre-hypertension, Hypertension
Interventions
aliskiren 300 mg once daily, Placebo/sugar pill
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 28, 2026, 7:47 PM EDT
Enrolling by invitation Phase 3 Interventional

Long-Term Open-Label Extension Study of Oral Levosimendan

NCT07436689
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT02059278
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
T-2345, Xalatan
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 28, 2026, 7:47 PM EDT
Recruiting Not applicable Interventional

Inspire HER: Inspiring the Heart and Emotions for Radical Health

NCT06966258
View directory record Official record
Conditions
Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Diseases, Hypertension, Diabetes, Hyperlipidemia, Kidney Disease, Obesity, Smoking
Interventions
Inspire HER Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years to 79 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 28, 2026, 7:47 PM EDT
Terminated Not applicable Interventional

Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation

NCT01952743
View directory record Official record
Conditions
Atrial Fibrillation, Hypertension
Interventions
AF ablation with Renal Denervation, AF ablation alone
Procedure
Lead sponsor
Siva Mulpuru
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Phase 4 Interventional Results available

Steroids After Laser Trabeculoplasty for Glaucoma

NCT00981435
View directory record Official record
Conditions
Glaucoma
Interventions
Prednisolone 1%, Ketorolac, Artificial Tears
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Miami, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 28, 2026, 7:47 PM EDT
Terminated Not applicable Interventional Results available

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

NCT01828255
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG) Patient
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
40 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 28, 2026, 7:47 PM EDT
Not listed Phase 2 Interventional

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

NCT06223048
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
AMDX-2011P
Drug
Lead sponsor
Amydis Inc.
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Not applicable Interventional Results available

Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients

NCT00357955
View directory record Official record
Conditions
Diabetes, Hypertension, Dyslipidemia, Coronary Arteriosclerosis
Interventions
Behavioral counseling and peer support, Interactive Education, Role modeling, Pharmacologic case management
Behavioral · Procedure
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 28, 2026, 7:47 PM EDT
Not yet recruiting Phase 4 Interventional

Biomarkers in Management of Post Partum Preeclampsia

NCT07478055
View directory record Official record
Conditions
Preeclampsia Severe, Preeclampsia Postpartum
Interventions
Magnesium Sulfate
Drug
Lead sponsor
Alexander Harrison
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 7:47 PM EDT
Withdrawn Phase 2 Interventional

Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension

NCT02108743
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension.
Interventions
Albuterol., Normal saline placebo
Drug
Lead sponsor
American Medical Association Foundation
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lifelight Non-Invasive Blood Pressure and Heart Rate Validation Study

NCT06535152
View directory record Official record
Conditions
Hypertension
Interventions
Lifelight, Manual sphygmomanometer
Device
Lead sponsor
Xim Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Timing of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese African Americans

NCT04021355
View directory record Official record
Conditions
Obesity, Hypertension, Circadian Dysregulation, Salt; Excess
Interventions
Oral sodium supplementation
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Not applicable Interventional Results available

The Health Access and Recovery Peer Program

NCT01725815
View directory record Official record
Conditions
Hypertension, Arthritis, Coronary Artery Disease, Hepatitis, Diabetes, Asthma, Hyperlipidemia, HIV
Interventions
HARP Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

NCT00147589
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
28
States / cities
Little Rock, Arkansas • Beverly Hills, California • Inglewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Phase 3 Interventional

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

NCT00355589
View directory record Official record
Conditions
Hypertension, Blood Pressure, High
Interventions
Ramipril and hydrochlorothiazide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Not applicable Interventional

Effect of a Grape Seed Extract (GSE) on Insulin Resistance

NCT01889368
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Grape Seed Extract, Placebo
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Phase 1Phase 2 Interventional

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

NCT01654484
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Not applicable Interventional

Veterans Walk for Health Study

NCT00123435
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes Mellitus, Hyperlipidemia, Hypertension, Obesity
Interventions
Nutritional counseling, Walking program, Simple pedometer, Enhanced pedometer
Behavioral · Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older · Male only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 28, 2026, 7:47 PM EDT
Enrolling by invitation Not applicable Interventional

Measurement of High Blood Pressure Using Boppli

NCT07547917
View directory record Official record
Conditions
Hypertension, Neonatal
Interventions
Boppli
Device
Lead sponsor
Indiana University
Other
Eligibility
0 Months to 9 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 28, 2026, 7:47 PM EDT
Completed Phase 2 Interventional

Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)

NCT00621816
View directory record Official record
Conditions
Hypertension
Interventions
nitroprusside, placebo infusion
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Little Rock, Arkansas • Stanford, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 28, 2026, 7:47 PM EDT
Completed No phase listed Observational

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

NCT01389206
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 28, 2026, 7:47 PM EDT
Terminated Phase 2Phase 3 Interventional

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

NCT05036135
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AV-101, Placebo
Drug
Lead sponsor
Aerovate Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 28, 2026, 7:47 PM EDT